Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
about
Molecular-targeted first-line therapy for advanced gastric cancerNew advances in targeted gastric cancer treatmentClinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinomaGastric biomarkers: a global reviewCurrent and emerging therapies in unresectable and recurrent gastric cancerCervical esophageal cancer: a gap in cancer knowledgePerioperative and Palliative Chemotherapy for Esophageal CancerFibroblast growth factor receptor signaling as therapeutic targets in gastric cancerAdvanced gastric cancer: Current treatment landscape and future perspectivesNovel targets in the treatment of advanced gastric cancer: a perspective reviewCurrent Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical ApplicationTargeted therapy for advanced gastric cancer: A review of current status and future prospectsChanging strategies for target therapy in gastric cancerPersonalized medicine in gastric cancer: Where are we and where are we going?Gastric cancer: The times they are a-changin'Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological featuresState of the art management of metastatic gastroesophageal cancerMolecular Dimensions of Gastric Cancer: Translational and Clinical PerspectivesEvaluation and treatment of malignant ascites secondary to gastric cancerClinical utility of ramucirumab in advanced gastric cancerMolecular classification of gastric cancer: Towards a pathway-driven targeted therapyMultimodal treatment of gastric cancer in the west: Where are we going?Strategies and Advancements in Harnessing the Immune System for Gastric Cancer ImmunotherapyAdvances in targeted therapies and new promising targets in esophageal cancerAdjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step ForwardNext-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyAdjuvant therapy for gastric cancer: what have we learned since INT0116?Targeting receptor tyrosine kinases in gastric cancerNovel CD9-targeted therapies in gastric cancerGastric Cancer: New Drugs - New StrategiesThe relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancersMolecular targeted therapy for the treatment of gastric cancerPositioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinomaLocally advanced gastroesophageal junction tumor: a treatment dilemmaFrom molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancerTranslating genomic profiling to gastrointestinal cancer treatment.Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions?Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.
P2860
Q26471049-A16154D9-11D7-40B4-899E-5DCB972DFC95Q26738548-F27D9F27-8353-4CCA-9DDB-F101106DB8D3Q26741530-F610EC39-D1F4-4399-9156-DA587F8002A4Q26741859-148165CB-0D1E-49EC-B39E-F2022289A75FQ26745453-DC91BE57-F4DA-4269-A869-E3588C1A01E6Q26749536-6229FC5F-3C49-4DF2-9134-8AC7D3E10DAFQ26753865-CF662273-0768-4CEB-A354-D57A13D4ACABQ26764932-11296D98-D729-4444-AB8E-8621F44A3095Q26764934-4D90A7B7-529C-48A3-9D09-84C440BBCD84Q26765208-4AB0EE41-1506-4CCF-ABDA-E953305128A3Q26765941-137EC014-A578-417D-AB4B-AD78ACF05CEEQ26774138-48464804-2F9E-4029-9CE2-E1F822172C58Q26774513-25CFF558-39C7-43F8-A67C-5686A2B482F1Q26774521-CDECD082-B482-4DA5-AFC3-CF94CB0E297CQ26776195-B2CED294-E2F2-4461-9E9A-2913F43E9F68Q26776198-3E352F72-5E6F-4293-A138-073E6CA5F24BQ26779217-92340967-A6FB-4EE5-BDB1-2DAA086E25E0Q26779725-E584AF37-5D68-4616-9953-E10D6B202B5BQ26780301-13B4E80D-39C0-42AA-8C0C-C8CE32E40FBAQ26785665-F20AC248-62BD-4BD7-9403-725E0370BE7EQ26798420-3B36ADDD-6F91-4D63-9D3B-821383F1491AQ26799748-8EF446E0-6583-4C7B-AF8A-71026A681EB8Q26823515-C495F33D-7753-4524-992F-8669D90C4B2CQ26825957-927F7FF4-3226-42E1-BAB4-3595913C80BCQ26858776-4DF3AECB-9FFF-40D5-8F80-634C95D4586FQ26992272-25CD90B1-0B47-4C9E-B998-AF5C7E55A925Q26993238-B2D8D11D-AC85-4364-A889-EF0577C8F14CQ27008675-DE64EB79-1A76-40A4-BDE0-A73E8B6C3173Q27013050-C55B6E85-EDD9-46A2-9D54-13C3696CC3B1Q27026877-BE6A60E2-FFB6-44D8-BD5A-970B93EC2915Q27028079-7D7EEDD6-5DED-4ED8-9876-5F6C0578382DQ27853223-BC578D6E-3C16-4928-B580-9CEC14F97A4AQ28066550-17ECE625-C6B3-47AA-913B-8567F6FDD96FQ28072433-25720168-D694-4554-B8CC-76E12FA498BBQ28079750-E3C13DDE-637F-4C22-8075-3D15EACDB063Q28082596-4E59F303-D752-4DDA-B6C5-DD6832FD46EBQ28082921-C7C716C9-58F8-4EFE-9D4C-CF771BE48B59Q30239109-71F3B32C-81BB-42A7-BF12-D31EC97E5F7AQ31012680-85F7C8CD-1759-468C-96BE-79FE92861A86Q33574315-9B821E6D-6D4C-4B4F-8723-09D34AB5051C
P2860
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Epirubicin, oxaliplatin, and c ...... sed, open-label phase 3 trial.
@en
type
label
Epirubicin, oxaliplatin, and c ...... sed, open-label phase 3 trial.
@en
prefLabel
Epirubicin, oxaliplatin, and c ...... sed, open-label phase 3 trial.
@en
P2093
P2860
P1433
P1476
Epirubicin, oxaliplatin, and c ...... sed, open-label phase 3 trial.
@en
P2093
Alicia Frances Clare Okines
Claire Saffery
Clare Okines
Clare Peckitt
David Ferry
David Gonzalez
David Smith
Fareeda Coxon
Gary Middleton
P2860
P304
P356
10.1016/S1470-2045(13)70096-2
P577
2013-04-15T00:00:00Z